29/120
1.2 / 5 stars
All 120 Win/Lose results shown below
PCRX Roast Me summary
Pacira BioSciences, Inc. (PCRX). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 0 wins, 12 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LosePCRX / S&P 12.26% / 15.20% |
LosePCRX / S&P PCRX unavailable / 15.00% |
LosePCRX / S&P PCRX unavailable / 50.40% |
| 2026-Q10/3 |
LosePCRX / S&P -12.67% / -4.33% |
LosePCRX / S&P PCRX unavailable / 11.30% |
LosePCRX / S&P PCRX unavailable / 27.70% |
| 2025-Q40/3 |
LosePCRX / S&P 0.43% / 2.65% |
LosePCRX / S&P PCRX unavailable / 9.00% |
LosePCRX / S&P PCRX unavailable / 13.40% |
| 2025-Q30/3 |
LosePCRX / S&P 7.82% / 8.12% |
LosePCRX / S&P PCRX unavailable / 4.61% |
LosePCRX / S&P PCRX unavailable / 13.45% |
| 2025-Q20/3 |
LosePCRX / S&P -3.82% / 10.94% |
LosePCRX / S&P PCRX unavailable / 4.83% |
LosePCRX / S&P -308.27% / 10.63% |
| 2025-Q11/3 |
WinPCRX / S&P 31.90% / -4.27% |
LosePCRX / S&P PCRX unavailable / 4.98% |
LosePCRX / S&P -256.55% / 10.57% |
| 2024-Q41/3 |
WinPCRX / S&P 25.18% / 2.41% |
LosePCRX / S&P PCRX unavailable / 5.25% |
LosePCRX / S&P -341.57% / 6.15% |
| 2024-Q30/3 |
LosePCRX / S&P -47.40% / 5.89% |
LosePCRX / S&P PCRX unavailable / 5.89% |
LosePCRX / S&P -2333.33% / 6.11% |
| 2024-Q20/3 |
LosePCRX / S&P -2.09% / 4.28% |
LosePCRX / S&P PCRX unavailable / 5.38% |
LosePCRX / S&P PCRX unavailable / 5.12% |
| 2024-Q10/3 |
LosePCRX / S&P -13.40% / 10.56% |
LosePCRX / S&P PCRX unavailable / 5.71% |
LosePCRX / S&P PCRX unavailable / 5.59% |
| 2023-Q41/3 |
LosePCRX / S&P 9.97% / 11.69% |
LosePCRX / S&P PCRX unavailable / 6.81% |
WinPCRX / S&P 161.76% / 7.78% |
| 2023-Q30/3 |
LosePCRX / S&P -23.43% / -3.27% |
LosePCRX / S&P PCRX unavailable / 7.52% |
LosePCRX / S&P -78.57% / -5.03% |
| 2023-Q20/3 |
LosePCRX / S&P -1.81% / 8.74% |
LosePCRX / S&P PCRX unavailable / 9.50% |
LosePCRX / S&P -119.28% / -8.57% |
| 2023-Q10/3 |
LosePCRX / S&P 5.70% / 7.50% |
LosePCRX / S&P PCRX unavailable / 10.77% |
LosePCRX / S&P -131.76% / -15.69% |
| 2022-Q40/3 |
LosePCRX / S&P -27.41% / 7.56% |
LosePCRX / S&P PCRX unavailable / 11.88% |
LosePCRX / S&P -63.04% / -17.99% |
| 2022-Q30/3 |
LosePCRX / S&P -8.77% / -4.88% |
LosePCRX / S&P PCRX unavailable / 13.47% |
LosePCRX / S&P -68.89% / -1.41% |
| 2022-Q20/3 |
LosePCRX / S&P -23.61% / -16.10% |
LosePCRX / S&P PCRX unavailable / 13.71% |
LosePCRX / S&P -78.72% / 11.04% |
| 2022-Q11/3 |
WinPCRX / S&P 26.84% / -4.60% |
LosePCRX / S&P PCRX unavailable / 15.97% |
LosePCRX / S&P -74.32% / 42.23% |
| 2021-Q41/3 |
LosePCRX / S&P 7.45% / 11.03% |
WinPCRX / S&P 26.04% / 15.00% |
LosePCRX / S&P -72.37% / 96.40% |
| 2021-Q30/3 |
LosePCRX / S&P -7.71% / 0.58% |
LosePCRX / S&P PCRX unavailable / 10.77% |
LosePCRX / S&P -52.46% / 69.42% |
| 2021-Q20/3 |
LosePCRX / S&P -13.43% / 8.55% |
LosePCRX / S&P PCRX unavailable / 6.58% |
LosePCRX / S&P PCRX unavailable / 51.81% |
| 2021-Q11/3 |
WinPCRX / S&P 17.13% / 6.17% |
LosePCRX / S&P PCRX unavailable / -1.06% |
LosePCRX / S&P PCRX unavailable / 7.39% |
| 2020-Q41/3 |
LosePCRX / S&P -0.47% / 12.15% |
WinPCRX / S&P 2.05% / -3.72% |
LosePCRX / S&P PCRX unavailable / -33.42% |
| 2020-Q32/3 |
WinPCRX / S&P 14.58% / 8.93% |
WinPCRX / S&P 6.95% / -2.04% |
LosePCRX / S&P PCRX unavailable / -27.10% |
| 2020-Q22/3 |
WinPCRX / S&P 56.49% / 20.54% |
WinPCRX / S&P 9.62% / -0.46% |
LosePCRX / S&P PCRX unavailable / -27.11% |
| 2020-Q11/3 |
LosePCRX / S&P -25.98% / -19.60% |
WinPCRX / S&P 23.00% / 3.47% |
LosePCRX / S&P PCRX unavailable / -14.75% |
| 2019-Q42/3 |
WinPCRX / S&P 18.99% / 9.07% |
WinPCRX / S&P 24.83% / 5.36% |
LosePCRX / S&P PCRX unavailable / 2.99% |
| 2019-Q31/3 |
LosePCRX / S&P -12.46% / 1.70% |
WinPCRX / S&P 22.56% / 5.02% |
LosePCRX / S&P PCRX unavailable / 0.21% |
| 2019-Q22/3 |
WinPCRX / S&P 14.27% / 4.30% |
WinPCRX / S&P 22.07% / 6.64% |
LosePCRX / S&P PCRX unavailable / 8.65% |
| 2019-Q11/3 |
LosePCRX / S&P -11.53% / 13.65% |
WinPCRX / S&P 21.25% / 8.12% |
LosePCRX / S&P PCRX unavailable / 14.29% |
| 2018-Q42/3 |
WinPCRX / S&P -12.47% / -13.52% |
WinPCRX / S&P 17.67% / 9.05% |
LosePCRX / S&P PCRX unavailable / 18.23% |
| 2018-Q32/3 |
WinPCRX / S&P 53.35% / 7.71% |
WinPCRX / S&P 14.54% / 10.21% |
LosePCRX / S&P PCRX unavailable / 19.06% |
| 2018-Q20/3 |
LosePCRX / S&P 2.89% / 3.43% |
LosePCRX / S&P 8.40% / 9.03% |
LosePCRX / S&P PCRX unavailable / 14.46% |
| 2018-Q10/3 |
LosePCRX / S&P -31.76% / -0.76% |
LosePCRX / S&P 4.20% / 7.68% |
LosePCRX / S&P PCRX unavailable / 12.46% |
| 2017-Q41/3 |
WinPCRX / S&P 21.57% / 6.64% |
LosePCRX / S&P 3.71% / 7.03% |
LosePCRX / S&P PCRX unavailable / 13.82% |
| 2017-Q30/3 |
LosePCRX / S&P -21.28% / 4.48% |
LosePCRX / S&P 2.81% / 5.68% |
LosePCRX / S&P PCRX unavailable / 17.57% |
| 2017-Q22/3 |
WinPCRX / S&P 4.61% / 3.09% |
WinPCRX / S&P 5.56% / 4.83% |
LosePCRX / S&P PCRX unavailable / 17.74% |
| 2017-Q12/3 |
WinPCRX / S&P 41.18% / 6.07% |
WinPCRX / S&P 9.38% / 3.67% |
LosePCRX / S&P PCRX unavailable / 13.32% |
| 2016-Q41/3 |
LosePCRX / S&P -5.61% / 3.82% |
WinPCRX / S&P 10.99% / 2.09% |
LosePCRX / S&P -2650.00% / 7.05% |
| 2016-Q31/3 |
LosePCRX / S&P 1.45% / 3.85% |
WinPCRX / S&P 12.97% / 0.20% |
LosePCRX / S&P PCRX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | PCRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -3.45% | 20.78% |
| Annualized return | -3.45% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | PCRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -56.57% | 83.14% |
| Annualized return | -15.36% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | PCRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -36.21% | 319.30% |
| Annualized return | -4.40% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |